Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

Contributed by: Business Wire

Tags

Biotechnology
Health
Pharmaceutical
Clinical Trials
Oncology
Iksuda Therapeutics

More Like This

Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

Iksuda to Present IKS014 Phase 1 Data at ESMO

Iksuda Therapeutics Receives FDA IND Clearance for IKS014

Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas

Iksuda to Present Growing ADC Pipeline at AACR

Business Wire logo

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

PR Newswire associated0

Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma